Atea Pharmaceuticals, Inc. develops oral therapies to address unmet medical needs in patients with severe viral diseases. The company's lead product candidate is a combination regimen of bemnifosbuvir, a nucleotide polymerase inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trials for the treatment of the hepatitis C virus (HCV). Atea is also advancing AT-587, currently in Phase 1 clinical trials for chronic hepatitis E virus (HEV) infection, and has previously explored treatments for COVID-19 and Dengue. The company operates primarily in the United States and utilizes contract manufacturing organizations to supply its clinical and potential commercial inventory. Atea generates no product revenue as it currently has no FDA-approved products on the market.
